An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2010
At a glance
- Drugs PF 2413873 (Primary)
- Indications Endometriosis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 22 Oct 2010 Planned end date changed from 1 Jun 2009 to 1 May 2009 as reported by ClinicalTrials.gov.
- 22 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual initiation date (Apr 2009) added as reported by ClinicalTrials.gov.